Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Disorders Clear all
Completed Phase 2 Interventional Results available

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

NCT01496976
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 14, 2026, 1:03 AM EDT
Withdrawn Not applicable Interventional

Continual vs. Routine Home Blood Pressure Monitoring and Management in Diverse Community Practice: CHANGE-BP

NCT05746117
View directory record Official record
Conditions
Hypertension
Interventions
Aktiia Device, Upper arm cuff
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 14, 2026, 1:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

NCT04785989
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
[U-13C]glucose, [13C5]glutamine
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 14, 2026, 1:03 AM EDT
Completed No phase listed Observational

C-Reactive Protein as a Predictor of Stem Cell Transplant Complications

NCT00179868
View directory record Official record
Conditions
Cancer, Leukemia, Stem Cell Transplantation
Interventions
C-Reactive Protein levels
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 14, 2026, 1:03 AM EDT
Terminated Not applicable Interventional

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

NCT02226497
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
Device · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 14, 2026, 1:03 AM EDT
Completed No phase listed Observational

Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition

NCT01390610
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Blood Glucose Monitoring
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center

NCT00267410
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Healthy Relationships
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 24 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

NCT00000810
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 14, 2026, 1:03 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313
View directory record Official record
Conditions
Lymphoma, Leukemia, Cancer
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

NCT00001049
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 14, 2026, 1:03 AM EDT
Recruiting No phase listed Observational

MicroRNAs as Biomarkers for Obstructive Sleep Apnea

NCT06189755
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Positive Airway Pressure
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Timeline
2024 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 14, 2026, 1:03 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Thromboelastography (TEG) In the Intrauterine Growth Restriction (IUGR) Neonatal Population by Gestational Age

NCT04907578
View directory record Official record
Conditions
Intrauterine Growth Restriction
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 14, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities

NCT06428643
View directory record Official record
Conditions
Chlamydia, Gonorrhea, Hiv, Syphilis
Interventions
Chlamydia, gonorrhea, syphilis, and HIV screening
Other
Lead sponsor
Tulane University
Other
Eligibility
15 Years to 26 Years
Enrollment
2,322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

NCT00000740
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00024440
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, oblimersen sodium, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Berkeley Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

NCT05564650
View directory record Official record
Conditions
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions
Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Drug · Procedure + 1 more
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 14, 2026, 1:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

NCT00793650
View directory record Official record
Conditions
Cancer, Multiple Myeloma
Interventions
Bortezomib, Melphalan, Autologous PBSC Transplant
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2012 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Center for Stroke Disparities Solution - Community Transitions Intervention

NCT01918891
View directory record Official record
Conditions
Hypertension, Stroke, Transient Ischemic Attack
Interventions
Nurse Practitioner Only, Nurse Practitioner + Health Coach
Behavioral
Lead sponsor
Visiting Nurse Service of New York
Other
Eligibility
21 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 14, 2026, 1:03 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers

NCT00900497
View directory record Official record
Conditions
Solid Tumors
Interventions
White Blood Cells/Granulocytes
Biological
Lead sponsor
Dipnarine Maharaj
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women.

NCT03716960
View directory record Official record
Conditions
Elevated Blood Pressure, Hypertension
Interventions
Pumpkin Seed Oil, Placebo
Other
Lead sponsor
Marymount University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 14, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

NCT01772420
View directory record Official record
Conditions
Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
Interventions
Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Kansas City, Kansas • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 14, 2026, 1:03 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06291220
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Obinutuzumab, ABBV-453
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Billings, Montana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 14, 2026, 1:03 AM EDT